Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,587 shares of the medical equipment provider’s stock after acquiring an additional 4,429 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Hologic were worth $1,826,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of HOLX. Massmutual Trust Co. FSB ADV grew its stake in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares during the period. Graypoint LLC increased its holdings in Hologic by 3.9% in the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Hologic by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after acquiring an additional 165 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Hologic by 11.5% during the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 189 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Hologic by 0.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after acquiring an additional 192 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 1.2 %

HOLX opened at $81.39 on Friday. The firm has a market capitalization of $18.99 billion, a price-to-earnings ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The company’s 50 day simple moving average is $80.82 and its two-hundred day simple moving average is $77.12. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.93 earnings per share. Analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on HOLX shares. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, September 17th. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Evercore ISI boosted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. upped their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.